| Overview |
| bs-11822R-PE |
| CSAD Polyclonal Antibody, PE Conjugated |
| WB |
| Mouse, Rat |
| Human, Dog, Horse |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CSAD |
| 401-493/493 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 51380 |
| Cytoplasm, Extracellular matrix |
| CSAD; CSAD_HUMAN; CSD; Cysteine sulfinic acid decarboxylase; Cysteine-sulfinate decarboxylase; Sulfinoalanine decarboxylase. |
| CSAD is a 493 amino acid protein that exists as a homodimer and belongs to the group II decarboxylase family. CSAD catalyzes the conversion of 3-sulfino-L-alanine to hypotaurine and carbon dioxide, binds pyridoxal phosphate as a cofactor and undergoes alternative splicing to produce three isoforms. The gene encoding CSAD maps to human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz